4-(3-氟苯基)-1H-咪唑 | 912763-49-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 4-(3-氟苯基)-1H-咪唑
• 英文名称: 4-(3-fluorophenyl)-1H-imidazole
• 英文别名: 5-(3-fluorophenyl)-1H-imidazole
• CAS: 912763-49-6
• 化学式: C₉H₇FN₂
• mdl: MFCD08669124
• 分子量: 162.166
• InChiKey: JCZROCCJDLYESM-UHFFFAOYSA-N

物化性质

• 熔点：
  94-95 °C
• 沸点：
  379.4±17.0 °C(Predicted)
• 密度：
  1.242±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  28.7
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  3-氟溴代苯乙酮 、 formamide 反应 0.25h， 生成 4-(3-氟苯基)-1H-咪唑
  参考文献：
  名称：

  从 1-芳基-2-溴乙酮、碳酸铵和脂肪族羧酸一锅合成 2-烷基-4(5)-芳基-1 H-咪唑

  摘要：

  在碳酸铵的存在下，从 α-溴芳基甲基酮和脂肪族羧酸开始制备 2-烷基-4(5)-芳基-1H-咪唑的简单有效的方案已经开发出来。

  DOI：

  10.3184/174751914x13932684206700

文献信息

• One-Pot Synthesis of 2-Alkyl-4(5)-Aryl-1<i>H</i>-Imidazoles from 1-Aryl-2-Bromoethanones, Ammonium Carbonate and Aliphatic Carboxylic Acids
  作者：Cong Liu、Yijiao Nie、Guowei Yao、Rongji Dai、Yulin Deng

  DOI：10.3184/174751914x13932684206700

  日期：2014.4

  A simple and efficient protocol for the preparation of 2-alkyl-4(5)-aryl-1H-imidazoles starting from α-bromo aryl methyl ketones and aliphatic carboxylic acids in the presence of ammonium carbonate has been developed.

  在碳酸铵的存在下，从 α-溴芳基甲基酮和脂肪族羧酸开始制备 2-烷基-4(5)-芳基-1H-咪唑的简单有效的方案已经开发出来。
• Novel imidazothiazoles and imidazoxazoles
  申请人：Calderwood David J.

  公开号：US20080161341A1

  公开（公告）日：2008-07-03

  The present invention is directed to novel compounds of formula (I) wherein the variables are as defined herein. The compounds of formula (I) are useful as kinase inhibitors and as such would be useful in treating certain conditions and diseases, especially inflammatory conditions and diseases and proliferative disorders and conditions, for example, cancers.

  本发明涉及公式（I）的新化合物，其中变量如定义所述。公式（I）的化合物可用作激酶抑制剂，因此可用于治疗某些病症和疾病，特别是炎症性病症和疾病以及增殖性疾病和病症，例如癌症。
• IDO Inhibitors
  申请人：Mautino Mario R.

  公开号：US20110136796A1

  公开（公告）日：2011-06-09

  Presently provided are compounds according to the formula (I) or (II), and pharmaceutical compositions comprising the compounds, wherein R 1 , R 4 , and R 5 are defined herein. Such compounds and compositions are useful for modulating an activity of indoleamine 2,3-dioxygenase; treating indoleamine 2,3-dioxygenase (IDO) mediated immunosuppression; treating a medical conditions that benefit from the inhibition of enzymatic activity of indoleamine -2,3-dioxygenase; enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent; treating tumor-specific immunosuppression associated with cancer; and treating immunosupression associated with an infectious disease.

  目前提供了按照公式(I)或(II)定义的化合物以及含有这些化合物的药物组合物，其中R1、R4和R5的定义在此处。这些化合物和组合物对于调节吲哚胺2,3-二氧化酶的活性；治疗吲哚胺2,3-二氧化酶(IDO)介导的免疫抑制；治疗从抑制吲哚胺-2,3-二氧化酶的酶活性中获益的医疗状况；增强包括给予抗癌剂的抗癌治疗的有效性；治疗与癌症相关的肿瘤特异性免疫抑制；以及治疗与传染性疾病相关的免疫抑制具有用处。
• [EN] INDOLEAMINE2,3-DIOXYGENASE INHIBITORS AND USES THEREOF IN PHARMACY<br/>[FR] INHIBITEURS INDOAMINE2, 3-DIOXYGÉNASE ET LEURS UTILISATIONS EN PHARMACIE<br/>[ZH] 吲哚胺2，3-双加氧酶抑制剂及其在药学中的用途
  申请人：SUZHOU GUOKUANG PHARMTECH CO LTD

  公开号：WO2018028491A1

  公开（公告）日：2018-02-15

  一种或多种吲哚胺2，3-双加氧酶的抑制剂化合物，包含该化合物的药物组分及制剂，及这类吲哚胺2，3-双加氧酶抑制剂的用途，可单一用药或与其它药物联合用药，用来治疗与吲哚胺2，3-双加氧酶相关的症状。
• Structure Based Development of Phenylimidazole-Derived Inhibitors of Indoleamine 2,3-Dioxygenase
  作者：Sanjeev Kumar、Daniel Jaller、Bhumika Patel、Judith M. LaLonde、James B. DuHadaway、William P. Malachowski、George C. Prendergast、Alexander J. Muller

  DOI：10.1021/jm800512z

  日期：2008.8.1

  Indoleamine 2,3-dioxygenase (IDO) is emerging as an important new therapeutic target for the treatment of cancer, chronic viral infections, and other diseases characterized by pathological immune suppression. With the goal of developing more potent IDO inhibitors, a systematic study of 4-phenylimidazole (4-PI) derivatives was undertaken. Computational docking experiments guided design and synthesis efforts with analogues of 4-PI. In particular, three interactions of 4-PI analogues with IDO were studied: the active site entrance, the interior of the active site, and the heme iron binding. The three most potent inhibitors (1, 17, and 18) appear to exploit interactions with C129 and S167 in the interior of the active site. All three inhibitors are approximately 10-fold more potent than 4-PI. The study represents the first example of enzyme inhibitor development with the recently reported crystal structure of IDO and offers important lessons in the search for more potent inhibitors.